XBiotech Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-45.5M | $-38.5M | $-24.6M | $-32.9M | $-17.4M | $-11.2M | $668.6M | $-21.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.7M | $1.7M | $1.7M | $2.6M | $2.6M | $2.2M | $2.4M | $2.4M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.6M | $1.8M | $3.3M | $5.1M | $4.5M | $12.6M | $3.4M | $1.7M |
| Net Cash from Operating Activities | $-39.9M | $-31.0M | $-18.7M | $-14.8M | $69.4M | $-65.1M | $-18.3M | $-16.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $289.0K | $1.3M | $362.0K | $585.0K | $3.5M | $3.7M | $204.0K | $122.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-289.0K | $-1.3M | $61.5M | $-63.9M | $-3.5M | $-3.7M | $674.8M | $-122.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | $0 | $75.0M | $0 | $0 | — |
| Stock Repurchases | — | $0 | $14.0K | $0 | — | — | — | — |
| Net Cash from Financing Activities | $-10.3M | $10.5M | $-9.0K | $0 | $-67.0M | $-409.7M | $42.1M | $201.0K |
| Net Change in Cash | $-47.1M | $-27.3M | $42.7M | $-79.7M | $-383.0K | $-477.2M | $698.8M | $-15.9M |
| Free Cash Flow | $-40.2M | $-32.3M | $-19.1M | $-15.4M | $65.9M | $-68.9M | $-18.5M | $-16.7M |